NeuroScientific Biopharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NSB.AX research report →
Price Chart
About the company
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments. Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
- CEO
- Nathan Smith
- IPO
- 2018
- Employees
- 9
- HQ
- Perth, WA, AU
Get TickerSpark's AI analysis on NSB.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $25.33M
- P/E
- -4.28
- PEG
- 0.02
- P/S
- 0.00
- P/B
- 1.31
- EV/EBITDA
- -8.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -19.10%
- ROIC
- -20.41%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-92,780-1.6%
- Op Income
- $-1,917,294
- Net Income
- $-1,845,513-669.2%
- EPS
- $-0.01-672.7%
- OCF Growth
- -2227.3%
- FCF Growth
- -2318.3%
- 52W High
- $0.19
- 52W Low
- $0.06
- 50D MA
- $0.06
- 200D MA
- $0.10
- Beta
- 1.12
- RSI (14)
- 53
- Avg Volume
- 340.20K
No earnings-call transcripts are available for NSB.AX yet.
- Free Float
- 59.0%
- Shares Outstanding
- 389.72M
- Float Shares
- 229.92M
Our NSB.AX coverage
Recent articles, reports, and earnings notes.
No research on NSB.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NSB.AX report →